Hans Sollinger of the University of Wisconsin, Madison will conduct the clinical trial with recombinant human C1 inhibitor (rhC1INH) under an investigator IND from the FDA. Recombinant human
In turn, this will permit the expansion of Interleukin Genetics’s distribution network for such genetic tests. Under the agreement, Access Business Group’s existing license to the Interleukin Genetics’s
Data from the study demonstrate that the 100mg/day cohort achieved a mean plasma viral load reduction of 1.87 log10 after seven days of treatment, similar to the potency
Proceeds from the financing will be used to fund near-term product launches, product development activities and strategic business initiatives. Jeffrey Yordon, CEO, founder and chairman of the board
The Invitrogen technology covered in these agreements involves methods and kits for substantially amplifying nucleic acids. It is reported to be useful in several common laboratory techniques, including
The Crooke patent estate is a family of patents stemming from the research of Stanley Crooke and others at Isis to identify and design RNA molecules that harness
Priority review is granted to applications for products that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, diagnosis or prevention of
These funds are part of a five-year grant totaling $1.9 million that the National Institutes of Health (NIH) awarded the company in September 2006 to study the underlying
This approval triggers the first in a series of three milestones to be paid by Janssen Pharmaceutica in relation to the initiation of the Fentanyl Taifun Phase III
The collaboration agreement between the two parties will terminate effective March 1, 2009; until that time, Bayer Schering Pharma will continue to provide continued supply of Vasovist in
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.